Bronchiectasis: a global disease necessitating global solutions
- PMID: 37105207
- DOI: 10.1016/S2213-2600(23)00136-4
Bronchiectasis: a global disease necessitating global solutions
Conflict of interest statement
SHC has received research grants from the Singapore Ministry of Health's National Medical Research Council and National Research Foundation and is on advisory boards for CSL Behring, Pneumagen, and Boehringer Ingelheim, has served on Data and Monitoring Boards (DSMB) for Inovio Pharmaceuticals, and has received personal fees from AstraZeneca and Chiesi Farmaceutici, all outside of the submitted work. RD has received grants from Glenmark and CIPLA, consulting fees from CIPLA, LUPIN, and Pfizer and personal fees from CIPLA, LUPIN, Glenmark, SUN Pharma, Pfizer, Glaxo Smith Kline, Sanofi, Zydus, and German Remedies, outside of the submitted work. PJM is primary site investigator for clinical trials sponsored by Insmed and Boehringer Ingelheim and has received consulting fees from Boehringer Ingelheim. ABC has received grants from the Australian National Health and Medical Research Council, royalties from UptoDate, support from the European Respiratory Society for travel, and served on DSMB for AstraZeneca, Glaxo Smith Kline, and Moderna.
Comment on
-
Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC).Lancet Respir Med. 2023 Jul;11(7):637-649. doi: 10.1016/S2213-2600(23)00093-0. Epub 2023 Apr 24. Lancet Respir Med. 2023. PMID: 37105206
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources